Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company pioneering AAV-based therapies for severe genetic disorders of the central nervous system. This page aggregates official news and press releases related to TSHA's innovative pipeline, regulatory progress, and strategic initiatives.
Investors and industry professionals will find timely updates on clinical trial developments, including TSHA-102 for Rett syndrome, regulatory designations like RMAT status, and research collaborations advancing gene therapy science. The curated collection serves as a centralized resource for tracking milestones in TSHA's mission to address unmet needs in monogenic CNS diseases.
Content spans multiple categories including therapy development updates, manufacturing advancements, partnership announcements with academic institutions, and financial disclosures. All materials maintain factual reporting on completed events without speculative commentary.
Bookmark this page for streamlined access to verified information about TSHA's progress in developing transformative genetic medicines. Check regularly for new developments in their clinical programs and scientific innovations.
Taysha Gene Therapies (Nasdaq: TSHA) announced a loan agreement with Silicon Valley Bank providing up to $100 million in financing. Of this, $40 million is available at closing, with Taysha having drawn $30 million so far. This non-dilutive financing will enhance Taysha's financial flexibility to pursue various milestones, including a potential regulatory approval for TSHA-120 in giant axonal neuropathy. The interest rate for the loan will be the greater of 7.0% or the WSJ Prime Rate plus 3.75%.
Taysha Gene Therapies (Nasdaq: TSHA) will report its second-quarter financial results for the period ending June 30, 2021, on August 16, 2021, at 8:00 AM ET. This pivotal-stage gene therapy company focuses on AAV-based therapies targeting monogenic central nervous system diseases. The company aims to provide updates on their progress and future outlook during the conference call.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming virtual conferences. The BTIG Virtual Biotechnology Conference will take place on August 9, 2021, at 11:30 am ET, featuring a fireside chat with key executives including the President and CEO, RA Session II, and others. Additionally, the Wedbush Pacgrow Healthcare Virtual Conference is scheduled for August 11, 2021, at 8:35 am ET, where the same executives will participate in a panel discussion. Webcasts for both events will be available on Taysha's corporate website.
Taysha Gene Therapies (Nasdaq: TSHA) announced a virtual manufacturing day for analysts and investors, scheduled for July 27, 2021, from 10:00 a.m. to 1:00 p.m. ET. The event will cover the company’s manufacturing capabilities, regulatory environment, and gene therapy immunology, followed by Q&A sessions. Presentations will feature senior leaders, including Frederick Porter, Greg Gara, and Suyash Prasad. Registration is available via LifeSci Events, and a live video webcast will also be accessible. Taysha is committed to developing AAV-based gene therapies for monogenic CNS diseases.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2021. The event is scheduled for July 15, 2021, at 11:00 am ET, featuring a fireside chat format. Key executives, including RA Session II (President and CEO), Dr. Suyash Prasad (Chief Medical Officer), and Kamran Alam (Chief Financial Officer), will participate. A live webcast will be accessible via Taysha's website, with an archived version available for 60 days. Taysha focuses on developing gene therapies for central nervous system diseases.
Taysha Gene Therapies (Nasdaq: TSHA) announced the publication of new analyses of natural history data for TSHA-120 in giant axonal neuropathy (GAN) in the journal Brain. The study assessed 45 patients aged 3-21 with genetically confirmed GAN to explore genotype-phenotype correlations and markers of disease severity. The findings indicate a clinical difference between early-onset and late-onset GAN patients, with early-onset showing more severe progression. Taysha aims to leverage these insights to support its ongoing clinical trials and regulatory discussions for TSHA-120, expected to report data later this year.
Taysha Gene Therapies (Nasdaq: TSHA) announced its first virtual R&D day for analysts and investors on June 28-29, 2021. The event will showcase the company's progress in AAV-based gene therapies targeting monogenic CNS diseases. Key discussions will include programs like TSHA-120 for giant axonal neuropathy and TSHA-101 for GM2 gangliosidosis. Senior leaders and experts will present, with webcasts available live and archived for 60 days. Registration is open via LifeSci Events. Taysha aims to accelerate the development of curative treatments for rare CNS disorders.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced its participation in two upcoming virtual fireside chats at major biotechnology conferences on June 22, 2021. The first event is the LifeSci Genetics Medicine Conference at 10:00 am ET, while the second is the LSX Biotech Growth CEO Forum at 1:10 pm ET, focusing on optimizing value from discovery platforms. Key executives, including the CEO and CMO, will participate in these discussions. Webcasts will be available for 60 days on Taysha's corporate website.
Taysha Gene Therapies (Nasdaq: TSHA) announced its first annual stockholder meeting will take place on June 17, 2021, at 10 am ET via webcast. The meeting can be accessed through the company’s corporate website. Taysha focuses on developing AAV-based gene therapies for monogenic diseases affecting the central nervous system, with a commitment to translating therapies from bench to bedside. Their integrated approach aims to improve patient lives through innovative treatments.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is participating in multiple upcoming healthcare conferences. The company will host a virtual fireside chat at:
- Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 am ET
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 5:30 pm ET
- JMP Securities Life Science Conference on June 16, 2021, at 12:30 pm ET
Featured participants include RA Session II, Dr. Suyash Prasad, and Kamran Alam. Webcasts will be available for 60 days on their corporate website.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
